Alzheimer s & Dementia Translational Research & Clinical InterventionsNeurosciencePeer-reviewed journal article
AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery
Frances Potjewyd, Joel K. Annor‐GyamfiiD, Jeffrey AubéiD, Shaoyou Chu, Ivie L. Conlon, Kevin J. FrankowskiiD, Shiva Krishna Reddy GuduruiD, Brian P. HardyiD, Megan D. Hopkins, Chizuru Kinoshita, Dmitri KireeviD, Emily R. Mason, Charles Travis MoerkiD, Felix O. Nwogbo, Kenneth H. PearceiD, Timothy I. RichardsoniD, David Anthony RogersiD, Disha M. Soni, Michael A. Stashko, Xiaodong WangiD, Carrow I. WellsiD, Timothy Mark WillsoniD, Stephen V. FryeiD, Jessica E. YoungiD, Alison Donnelly AxtmaniD
Abstract
IntroductionThe portfolio of novel targets to treat Alzheimers disease (AD) has been enriched by the AMP-AD program. MethodsA cheminformatics-driven effort enabled identification of existing small molecule modulators for many protein targets nominated by AMP-AD and suitable positive control compounds to be included in the set. ResultsWe have built an annotated set of 171 small molecule modulators, including mostly inhibitors, targeting 98 unique proteins that have been nominated by AMP-AD consortium members as novel targets for AD treatment. These small molecules vary in their quality and should be considered chemical tools that can be used in efforts to validate therapeutic hypotheses, but which would require further optimization. A physical copy of the AD Informer Set can be ordered via the AD Knowledge Portal. DiscussionSmall molecule tools that enable target validation are important tools for the translation of novel hypotheses into viable therapeutic strategies for AD.
- Citations
- 6
- FWCI
- 0.77
- Field percentile
- top 33%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Morphing Cholinesterase Inhibitor Amiridine into Multipotent Drugs for the Treatment of Alzheimer's Disease
Eva Mezeiová, Lukáš Prchal, … Jan Korábečný·Biomedicine & PharmacotherapyPeer-reviewed·Mar 15, 2024
- Network Pharmacology and molecular docking approach to unveil the mechanism of Hypericum perforatum in the management of Alzheimer's disorder
V. Dogra, M. Choudhary, … N. Goyat·bioRxiv·May 26, 2023
- Pharmacophore-driven Identification of N-Methyl-D-Receptor Antagonists as Potent Neuroprotective Agents Validated Using In-Vivo Studies
Mukta Sharma, Anupama Mittal, … Sarvesh Paliwal·Biology Methods and ProtocolsPeer-reviewed·Jan 1, 2020
- Screening of herbal molecules for the management of Alzheimer's Disorder through molecular docking and in-vitro investigation
P. Nagu, A. K. A. Pathan, V. Mehta·bioRxiv·Jan 1, 2023
- An AI-Driven Framework for Discovery of BACE1 Inhibitors for Alzheimer's Disease
Evan Xie, Karin Hasegawa, … Yuefan Deng·bioRxiv·May 15, 2024
- In silico study of selected alkaloids as dual inhibitors of β and γ-Secretases for Alzheimer's disease
Isreal Ayobami Onifade, Haruna Isiyaku Umar, … Nike Jesutofunmi Idowu·Journal of Alzheimer s DiseasePeer-reviewed·Feb 1, 2025